Neoplasm

Exomes were sequenced from two cohorts of non small cell lung cancer patients who were treated with pembrolizumab. In a discovery cohort of 16 patients, durable clinical benefit (DCB - partial or stab… (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

A retrospective analysis from three cancer centres in China examined the use of pembrolizumab, as monotherapy or combined with chemotherapy, in 116 patients with MSI-high or TMB-high advanced solid tu… (full text at CIViC)

PMID 38451314 · Yan et al., 2024 · Open in CIViC

This study analyzed over 300 patient with advanced solid tumors and melanoma across 22 tumor types from four KEYNOTE clinical trials to define genomic and immune predictors of response to pembrolizuma… (full text at CIViC)

PMID 30309915 · Cristescu et al., 2018 · Open in CIViC

Microsatellite instability-high (MSI-H) colorectal cancers (CRC) respond to immune checkpoint inhibitors (ICPIs), but response rates vary, often < 50%, highlighting the need for better stratification.… (full text at CIViC)

PMID 31038663 · Schrock et al., 2019 · Open in CIViC

A 54-year-old female with recurrent stage IV ACC that progressed after adrenalectomy, radiation, and mitotane had a TMB-high (11.6 mutations/Mb), MSS, PD-L1-negative tumor with a markedly clonal molec… (full text at CIViC)

PMID 42158873 · Nakhleh et al., 2026 · Open in CIViC

This analysis of the Phase 2 KEYNOTE-782 trial (NCT03664024) evaluated the correlation of blood tumor mutational burden (bTMB) with the efficacy of first-line pembrolizumab plus platinum-based chemoth… (full text at CIViC)

PMID 38422883 · Bar et al., 2024 · Open in CIViC

Temozolomide (TMZ), the principal alkylating agent used in PanNET, drives acquisition of a hypermutator phenotype through direct mutagenesis. In a paired pre/post-TMZ cohort (23 patients), a hypermuta… (full text at CIViC)

PMID 41244370 · Taboada et al., 2025 · Open in CIViC

This is part of a randomised phase 3 trial, CheckpOiNt Blockade For the Inihibition of Relapsed Mesothelioma (CONFIRM), that examined therapeutic response to the anti-PD1 inhibitor, nivolumab, in pati… (full text at CIViC)

PMID 40691143 · Fennell et al., 2025 · Open in CIViC

This is part of the randomised double-blind phase 3 trial, CameL-sq, a study that assessed the therapeutic effectiveness of the PD-1 blockade, camrelizumab plus chemotherapy as first-line treatment in… (full text at CIViC)

PMID 34980131 · Jiang et al., 2022 · Open in CIViC

TMPRSS2/ERG gene fusion was observed in 23 of 29 (79%) of prostate carcinoma samples, and 90% of ERG expression positive prostate carcinoma samples.

PMID 16254181 · Tomlins et al., 2005 · Open in CIViC

TMPRSS2-ETV1 fusions are recurrent in prostate cancers.

PMID 16254181 · Tomlins et al., 2005 · Open in CIViC

Non-invasive detection of multiple TMPRSS2:ERG fusion mutations in urine samples of patients with prostate cancer. Rapid 60 minute screening using DNA ligase and isothermal amplification to detect m… (full text at CIViC)

PMID 27865106 · Koo et al., 2017 · Open in CIViC

The authors analyzed 96 diffuse large B-cell lymphomas and identified several recurrently mutated genes

PMID 28327945 · Albuquerque et al., 2017 · Open in CIViC

In a clinical study including 106 patients, over expression of TNC-L is significantly associated with decreased OS by a multivariate analysis (p = 0.0005).

PMID 31463696 · Hagiwara et al., 2020 · Open in CIViC

In an in vitro study, an increased gemcitabine IC50 significantly correlated with increased concentration of TNfnA-D (TNC-L). Resistance reached a platform at 20 ug/ml (p < 0.01).

PMID 20686216 · Gong et al., 2010 · Open in CIViC

Focusing on ABC DLBCL, the authors showed that >50% of cases have somatic mutations in regulators of NF-KB with TNFAIP3 among the most common.

PMID 19412164 · Compagno et al., 2009 · Open in CIViC

This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC)

PMID 21796119 · Morin et al., 2011 · Open in CIViC

Low coverage WGS and WES was performed on 752 multiple myleoma patients. Structural variants (copy number gains, templated insertions, and or translocations) of TNFRS17 were found in 19 (2.5%) patient… (full text at CIViC)

PMID 33392515 · Rustad et al., 2020 · Open in CIViC

B-ALL cases with high-risk clinical features or suggestion of a kinase rearrangement were subjected to low density gene expression array to determine Ph-like status. 1 patient (6 years old) with a TN… (full text at CIViC)

PMID 25207766 · Roberts et al., 2014 · Open in CIViC

A patient harbouring a novel TNKS2–PDGFRA fusion in a myeloid neoplasm with eosinophilia demonstrated a dramatic and durable response upon treatment with Imatinib mono therapy.

PMID 25658984 · Chalmers et al., 2015 · Open in CIViC

This retrospective study of COG ALL cases from a 5 year period identified 10 of 40 T-ALL cases with an ABL1 rearrangement. One 3 year old patient had a novel complex rearrangement between TNRC6B and A… (full text at CIViC)

PMID 30803551 · Papenhausen et al., 2019 · Open in CIViC

The OncoBird framework utilizes data from the open-label, randomized phase III FIRE-3 trial, which involved patients with metastatic colorectal carcinoma who received either cetuximab or bevacizumab i… (full text at CIViC)

PMID 37666855 · Ohnmacht et al., 2023 · Open in CIViC

FFPE tumor samples from 78 patients with colorectal cancer, who had received irinotecan monotherapy were analyzed with a FISH dual-probe. TOP1 gain was nonsignificantly associated with objective respo… (full text at CIViC)

PMID 24256029 · Nygård et al., 2014 · Open in CIViC

TOP1 E418K mutation and TOP1 122fs contribute to acquired resistance to Sacituzumab Govitecan (SG) therapy through alterations in the drug target TOP1. The patient, a 42-year-old female with metastati… (full text at CIViC)

PMID 34404686 · Coates et al., 2021 · Open in CIViC

Shorter progression free survival was observed in patients with low expression (IHC) of topoisomerase 1 in 16 patients with relapsed or persistent ovarian or peritoneal carcinoma after treatment with … (full text at CIViC)

PMID 19648970 · Litzow et al., 2010 · Open in CIViC

498 patients were retrospectively analyzed for topoisomerase 1 expression (IHC). In the subgroup of patients treated with irinotecan (38% of the 498), those patients expressing Topoisomerase I had a b… (full text at CIViC)

PMID 19775480 · Kostopoulos et al., 2009 · Open in CIViC

In a retrospective study, TOP2A expression was assessed by IHC for 108 breast cancer patients (from TAX 303 trial). TOP2A expression was associated with a higher probability of response in doxorubicin… (full text at CIViC)

PMID 15486187 · Durbecq et al., 2004 · Open in CIViC

In an in vitro study, leukemia cells expressing TOP2A/90 show increased inhibition (p < 0.025) upon KD of TOP2A/90 when treated with etoposide. Moreover cells expressing TOP2A/170 but not TOP2A/90 sho… (full text at CIViC)

PMID 29514855 · Kanagasabai et al., 2018 · Open in CIViC

In an in vitro study, leukemia cells expressing TOP2A/90 show increased IC50 compared to leukemia cells underexpressing TOP2A/90 when treated with etoposide, daunorubicin, mAMSA, mitoxantrone and pixa… (full text at CIViC)

PMID 33446509 · Hernandez et al., 2021 · Open in CIViC

This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Some concerns about the validity of the results have been expressed in subs… (full text at CIViC)

PMID 28985567 · Reddy et al., 2017 · Open in CIViC

In a study of invasive ovarian carcinoma patients who had undergone surgery, the p53 alteration variant was defined as p53 mutation or p53 overexpression by immunostain (>10% positive). Patients with … (full text at CIViC)

PMID 11595686 · Reles et al., 2001 · Open in CIViC

This study evaluated 641 cases of rhabdomyosarcoma (RMS) that were enrolled in the Children’s Oncology Group (COG) trials from 1998 to 2017 and the UK malignant mesenchymal tumor and RMS2005 trails fr… (full text at CIViC)

PMID 34166060 · Shern et al., 2021 · Open in CIViC

UK Caucasians were enrolled in a large-scale GWAS study looking for loci associated with lung cancer susceptibility (1529 cases and 2707 controls). Of 64 nonsynonymous, single nucleotide polymorphisms… (full text at CIViC)

PMID 16741161 · Rudd et al., 2006 · Open in CIViC

A subset of 58 cancer cell lines with unaltered TP53 are sensitive to MDM2 inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 inhibitor.… (full text at CIViC)

PMID 25730903 · Saiki et al., 2015 · Open in CIViC

Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP… (full text at CIViC)

PMID 25730903 · Saiki et al., 2015 · Open in CIViC

Cys-238 was directly bound to zinc molecule. Patients with missense mutations affecting amino acids directly involved in DNA or zinc binding displayed a very aggressive clinical phenotype. When patien… (full text at CIViC)

PMID 11051239 · Alsner et al., 2000 · Open in CIViC

Patients with conserved domain p53 mutation (n=61) were compared with those with wild type or non-conserved domain p53 mutation (n=117) in a cohort of 178 invasive ovarian carcinoma patients who had u… (full text at CIViC)

PMID 11595686 · Reles et al., 2001 · Open in CIViC

Human mutant D281G p53 was stably transfected into the murine fibroblast (10)3 and human osteosarcoma SAOS-2 cell lines, which lack endogenous p53 expression, resulting in viable cells. In contrast, p… (full text at CIViC)

PMID 8099841 · Dittmer et al., 1993 · Open in CIViC

Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA). Mutations (434; 36%) had no prognostic effect (OBS: HROS=0.99; [95%CI 0.77-1.28], p=0.95; HR… (full text at CIViC)

PMID 26899019 · Ma et al., 2016 · Open in CIViC

In a study of 74 patients with head and neck squamous cell carcinoma, those with disruptive mutations in TP53 had shorter overall survival and a higher rate of locoregional recurrence than those witho… (full text at CIViC)

PMID 22090360 · Skinner et al., 2012 · Open in CIViC

Oral squamous cell carcinoma patients with TP53 mutations in the DNA binding domain (L2, L3 and the LSH motif) have significantly reduced cumulative survival when compared to patients with TP53 mutati… (full text at CIViC)

PMID 12509970 · Yamazaki et al., 2003 · Open in CIViC

In a study 202 breast cancer patients undergoing first line tamoxifen treatment, 65 patients had mutations in TP53. Among the p53 wild type population a 66% response rate was reported, where response … (full text at CIViC)

PMID 10786679 · Berns et al., 2000 · Open in CIViC

Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP… (full text at CIViC)

PMID 25730903 · Saiki et al., 2015 · Open in CIViC

Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP… (full text at CIViC)

PMID 25730903 · Saiki et al., 2015 · Open in CIViC